Utility of 68 Ga-FAPI-04 PET/CT in Adenoid Cystic Carcinoma Compared With 18 F-FDG PET/CT : Two Case Reports.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Jul 2023
01 Jul 2023
Historique:
medline:
7
6
2023
pubmed:
11
5
2023
entrez:
11
5
2023
Statut:
ppublish
Résumé
68 Ga-fibroblast activation protein inhibitor (FAPI) PET/CT is an emerging imaging modality with high sensitivity and high tumor-to-background ratio in various cancers including in the head and neck regions. The authors present 2 cases of adenoid cystic carcinoma who underwent 68 Ga-FAPI-04 and 18 F-FDG PET/CT. Locoregional recurrence has been detected more precisely in the first case with 68 Ga-FAPI-04. In the second case, 68 Ga-FAPI-04 outperformed 18 F-FDG in the number of lesions and demonstrated intense FAP uptake on widespread metastases, which could provide a treatment option as a theranostic concept. These cases highlight that 68 Ga-FAPI-04 PET/CT may be useful for detecting local recurrence and metastases and help select patients for radionuclide treatments targeting cancer-associated fibroblasts.
Identifiants
pubmed: 37167284
doi: 10.1097/RLU.0000000000004687
pii: 00003072-202307000-00036
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
68Ga-FAPI
0
Gallium-68
98B30EPP5S
Gallium Radioisotopes
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e350-e352Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Coca-Pelaz A, Rodrigo JP, Bradley PJ, et al. Adenoid cystic carcinoma of the head and neck—an update. Oral Oncol . 2015;51:652–661.
Ali S, Yeo JC-L, Magos T, et al. Clinical outcomes of adenoid cystic carcinoma of the head and neck: a single institution 20-year experience. J Laryngol Otol . 2016;130:680–685.
Jang S, Patel PN, Kimple RJ, et al. Clinical outcomes and prognostic factors of adenoid cystic carcinoma of the head and neck. Anticancer Res . 2017;37:3045–3052.
Jung J-H, Lee S-W, Son SH, et al. Clinical impact of 18 F-FDG positron emission tomography/CT on adenoid cystic carcinoma of the head and neck. Head Neck . 2017;39:447–455.
Wong WL. PET-CT for staging and detection of recurrence of head and neck cancer. Semin Nucl Med . 2021;51:13–25.
Kratochwil C, Flechsig P, Lindner T, et al. 68 Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med . 2019;60:801–805.
Syed M, Flechsig P, Liermann J, et al. Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. Eur J Nucl Med Mol Imaging . 2020;47:2836–2845.
Kuyumcu S, Sanli Y, Subramaniam RM. Fibroblast-activated protein inhibitor PET/CT: Cancer diagnosis and management. Front Oncol . 2021;11:758958.
Kuyumcu S, Kovan B, Sanli Y, et al. Safety of fibroblast activation protein-targeted radionuclide therapy by a low-dose dosimetric approach using 177 Lu-FAPI04. Clin Nucl Med . 2021;46:641–646.
Qin C, Liu F, Huang J, et al. A head-to-head comparison of 68 Ga-DOTA-FAPI-04 and 18 F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study. Eur J Nucl Med Mol Imaging . 2021;48:3228–3237.
Gu B, Xu X, Zhang J, et al. The added value of [ 68 Ga] Ga-DOTA-FAPI-04 PET/CT in patients with head and neck cancer of unknown primary with [ 18 F] FDG negative findings. 2021.
Röhrich M, Syed M, Liew DP, et al. 68 Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas—imaging analysis and histological validation. Radiother Oncol . 2021;160:192–201.